BioCryst Pharmaceuticals Inc. [NASDAQ: BCRX] surged by $0.06 during the normal trading session on Thursday and reaching a high of $16.72 during the day while it closed the day at $16.36. The company report on June 3, 2021 that BioCryst Launches ORLADEYO™ (berotralstat) in Germany.
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) announced that oral, once-daily ORLADEYO™ (berotralstat) is now available for patients with a prescription in Germany.
ORLADEYO was approved by the European Medicines Agency (EMA) on April 30, 2021 for the prevention of recurrent hereditary angioedema (HAE) attacks in HAE patients 12 years and older. The full European Summary of Product Characteristics (SMPC) for ORLADEYO is available on the EMA website at www.ema.europa.eu.
BioCryst Pharmaceuticals Inc. stock has also gained 20.21% of its value over the past 7 days. However, BCRX stock has inclined by 49.82% in the 3 months of the year. Over the past six months meanwhile, it has gained 235.93% and gained 119.60% year-on date.
The market cap for BCRX stock reached $2.72 billion, with 177.34 million shares outstanding and 176.16 million shares in the current float. Compared to the average trading volume of 5.08M shares, BCRX reached a trading volume of 3062269 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about BioCryst Pharmaceuticals Inc. [BCRX]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for BCRX shares is $16.56 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on BCRX stock is a recommendation set at 2.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Cowen have made an estimate for BioCryst Pharmaceuticals Inc. shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on March 01, 2021. While these analysts kept the previous recommendation, JP Morgan raised their target price to Overweight. The new note on the price target was released on September 29, 2020, representing the official price target for BioCryst Pharmaceuticals Inc. stock.
The Average True Range (ATR) for BioCryst Pharmaceuticals Inc. is set at 0.86, with the Price to Sales ratio for BCRX stock in the period of the last 12 months amounting to 84.97.
BCRX stock trade performance evaluation
BioCryst Pharmaceuticals Inc. [BCRX] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 20.21. With this latest performance, BCRX shares gained by 48.59% in over the last four-week period, additionally plugging by 235.93% over the last 6 months – not to mention a rise of 263.56% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for BCRX stock in for the last two-week period is set at 72.57, with the RSI for the last a single of trading hit 78.21, and the three-weeks RSI is set at 68.55 for BioCryst Pharmaceuticals Inc. [BCRX]. The present Moving Average for the last 50 days of trading for this stock 12.09, while it was recorded at 15.83 for the last single week of trading, and 8.11 for the last 200 days.
BioCryst Pharmaceuticals Inc. [BCRX]: An insightful look at the core fundamentals
Operating Margin for any stock indicates how profitable investing would be, and BioCryst Pharmaceuticals Inc. [BCRX] shares currently have an operating margin of -952.90 and a Gross Margin at +90.59. BioCryst Pharmaceuticals Inc.’s Net Margin is presently recorded at -1026.35.
Return on Total Capital for BCRX is now -131.36, given the latest momentum, and Return on Invested Capital for the company is -195.22. Return on Equity for this stock declined to -1,925.37, with Return on Assets sitting at -71.69. Additionally, BCRX Total Debt to Total Capital is recorded at 114.21, with Total Debt to Total Assets ending up at 46.24.
Reflecting on the efficiency of the workforce at the company, BioCryst Pharmaceuticals Inc. [BCRX] managed to generate an average of -$743,146 per employee. Receivables Turnover for the company is 1.16 with a Total Asset Turnover recorded at a value of 0.07.BioCryst Pharmaceuticals Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 2.70 and a Current Ratio set at 2.70.
Earnings per share (EPS) analysis for BioCryst Pharmaceuticals Inc. [BCRX] stock
With the latest financial reports released by the company, BioCryst Pharmaceuticals Inc. posted -0.24/share EPS, while the average EPS was predicted by analysts to be reported at -0.25/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 4.00%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for BCRX. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for BioCryst Pharmaceuticals Inc. go to 19.90%.
BioCryst Pharmaceuticals Inc. [BCRX]: Insider Ownership positions
There are presently around $1,713 million, or 60.00% of BCRX stock, in the hands of institutional investors. The top three institutional holders of BCRX stocks are: BLACKROCK INC. with ownership of 16,241,775, which is approximately -0.111% of the company’s market cap and around 0.80% of the total institutional ownership; BAKER BROS. ADVISORS LP, holding 12,710,818 shares of the stock with an approximate value of $207.95 million in BCRX stocks shares; and VANGUARD GROUP INC, currently with $158.69 million in BCRX stock with ownership of nearly -16.374% of the company’s market capitalization.
Positions in BioCryst Pharmaceuticals Inc. stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 102 institutional holders increased their position in BioCryst Pharmaceuticals Inc. [NASDAQ:BCRX] by around 18,346,973 shares. Additionally, 100 investors decreased positions by around 33,731,902 shares, while 17 investors held positions by with 52,624,344 shares. The mentioned changes placed institutional holdings at 104,703,219 shares, according to the latest SEC report filing. BCRX stock had 46 new institutional investments in for a total of 11,451,269 shares, while 31 institutional investors sold positions of 7,197,768 shares during the same period.